## Abstract The original article to which this Erratum refers was published in International Journal of Cancer (2003) 106(3) 416โ422
Differences in stage and therapy for breast cancer across Europe
โ Scribed by Milena Sant; Eurocare Working Group
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- French
- Weight
- 71 KB
- Volume
- 93
- Category
- Article
- ISSN
- 0020-7136
- DOI
- 10.1002/ijc.1408
No coin nor oath required. For personal study only.
โฆ Synopsis
We examined variations in stage, diagnostic workup and therapy for breast cancer across Europe. Seventeen cancer registries in six European countries contributed 4,480 cases diagnosed in 1990 -91. The clinical records of these cases were examined, and the distribution of stage, diagnostic examinations and therapy were analyzed. Stage was earliest in the French registries, followed by those of Italy and Eindhoven (Netherlands). The proportion of stage I cancers was highest in the French areas with screening in place. Estonia, the English registries and Granada (Spain) had the most advanced stage at diagnosis. Use of liver ultrasonography varied from 84% (Italian registries) to 18% (Granada). Bone scan use varied from 81% (Italian registries) to 15% (Mersey, UK). The highest proportions treated by breast-conserving surgery were in the French (57%) and English registries (63%); the lowest were in Estonia (6%) and Granada (11%). The highest proportions of Halsted mastectomies were in Italy (19%) and Granada (8%). In all countries except England, 90% of operations included axillary lymphadenectomy. Medical treatment only was given to 8% of (mostly advanced) cases overall. Estonia (21%) and the English registries (14%) had the highest proportions of patients given medication only. Chemotherapy was given to low proportions of nodepositive cases in the Italian (76%) and English (74%) areas; breast-conserving surgery for stage I tumors varied from 24% in Granada to 84% in England. These wide differences in breast cancer care across Europe in the early 1990s indicate a need for continual monitoring of past treatments to help ensure application of the most effective protocols.
๐ SIMILAR VOLUMES
## Abstract We used multiple regression models to assess the influence of disease stage at diagnosis on the 5โyear relative survival of 4,478 patients diagnosed with breast cancer in 1990โ1992. The cases were representative samples from 17 populationโbased cancer registries in 6 European countries
## Abstract Several patient and tumor factors go into the decision process to determine whether a breast cancer patient is a good candidate for breastโconserving therapy. The patient must be seen by all disciplines before any therapeutic intervention. When used appropriately, breastโconserving ther
## Abstract ## BACKGROUND: Radiationโinduced fatigue is a common side effect of breast cancer radiotherapy (RT). This study compares the induction and persistence of radiationโinduced fatigue in accelerated partial breast irradiation (APBI), accelerated hypofractionated RT, and standard whole brea
## Abstract Epidemiologic studies have shown an increased risk of breast cancer following hormone replacement therapy (HRT). The aim of this study was to investigate whether different treatment regimens or the androgenecity of progestins influence the risk of breast cancer differently. The Danish N